Loading...
01/10 17:15
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals several negative aspects: increased losses, higher expenses, and unclear management responses regarding key programs and partnerships. Despite some positive developments in clinical trials, the financial health and guidance remain concerning. The expansion into Asia is promising, but supply chain risks and regulatory hurdles pose challenges. The lack of clarity in management's responses during the Q&A further adds to uncertainty, leading to a negative sentiment.
General and Administrative Expenses Q4 2024 $1.6 million, up from $1.3 million in Q4 2023.
R&D Expenses Q4 2024 $4.3 million, up from $3.6 million in Q4 2023.
Net Loss Q4 2024 $5.9 million or $0.54 per share, compared to a net loss of $4.2 million or $0.39 per share in Q4 2023.
R&D Expenses Full Year 2024 $16.1 million, up from $11.9 million in 2023. The increase was primarily due to $2.95 million in research studies for clinical trials, $897,000 in payroll expenses, and $376,000 in consulting expenses.
General and Administrative Expenses Full Year 2024 $6.1 million, up slightly from $6 million in 2023, primarily due to increases in professional fees.
Net Loss Full Year 2024 $20.8 million or $1.93 per share, compared to $16 million or $1.47 per share in 2023.
Cash Position as of December 31, 2024 $24 million in cash, cash equivalents, and marketable securities.
Shares Outstanding as of December 31, 2024 10,784,725 shares of common stock, with a total fully diluted shares outstanding of approximately 12.1 million.
LP-300: LP-300 is in Phase 2 trials, targeting a $4 billion to $5 billion annual opportunity, with an 86% clinical benefit rate and a 43% objective response rate in never smoker non-small cell lung cancer patients.
LP-184: LP-184 has received FDA Fast Track designations for glioblastoma and triple negative breast cancer, with a market potential exceeding $10 billion.
LP-284: LP-284 is in Phase 1a trials, targeting solid tumors with a focus on DNA damage repair mutations.
STAR-001: STAR-001 is a new drug candidate developed through AI, targeting glioblastoma with a unique mechanism involving spironolactone.
Geographic Expansion: Lantern Pharma is expanding its clinical trials for LP-300 into Japan and Taiwan, where the incidence of non-small cell lung cancer among never smokers is significantly higher.
New Collaborations: Plans to initiate a trial in Nigeria for triple negative breast cancer, leveraging local expertise and higher incidence rates.
AI Platform RADR: The RADR platform has expanded to over 100 billion oncology-specific data points, enhancing precision oncology capabilities.
Operational Efficiency: Lantern's burn rate is significantly lower than industry peers, with an average cost of $2 million to $2.5 million per program to get into trials.
Agentic AI Development: Lantern is developing an agentic AI framework to enhance drug development efficiency and precision, aiming to transform oncology drug discovery.
Focus on Precision Oncology: The company is concentrating on developing therapies for specific cancer types with limited treatment options, supported by multiple FDA designations.
Regulatory Risks: The company faces regulatory risks associated with the FDA's approval processes for their drug candidates, particularly with the Fast Track designations for LP-184 and LP-300, which could expedite clinical development but also require stringent compliance.
Competitive Pressures: Lantern Pharma operates in a highly competitive environment, with peers reporting significantly higher burn rates and advanced pipelines, which could impact their market position and funding opportunities.
Financial Risks: The company reported a net loss of approximately $20.8 million for 2024 and anticipates needing substantial additional funding in the near future, which poses a risk to their operational continuity.
Supply Chain Challenges: The expansion of clinical trials into international markets such as Japan and Taiwan may introduce supply chain complexities and regulatory hurdles that could delay drug development.
Market Risks: The potential market for their drug candidates is substantial, but the actual realization of these opportunities is contingent on successful clinical outcomes and market acceptance, which are uncertain.
Clinical Trial Risks: The success of their drug candidates is heavily reliant on the outcomes of ongoing clinical trials, which carry inherent risks of failure or adverse results that could hinder future development.
AI and Machine Learning Integration: Lantern Pharma is leveraging AI and machine learning to transform precision oncology drug development, aiming for significant returns for investors and patients.
Clinical Pipeline Progress: All clinical stage drug candidates are in Phase 1 and Phase 2 trials, with multiple cohorts dosed and promising preliminary results reported.
Geographic Expansion: Strategic expansion into Japan and Taiwan for LP-300, targeting a growing patient population with non-small cell lung cancer.
Regulatory Designations: Two FDA Fast Track designations for LP-184 and three rare pediatric disease designations, expediting clinical development timelines.
Starlight Therapeutics: Development of Starlight Therapeutics, focusing on innovative trial designs and leveraging AI for drug discovery.
Agentic AI Development: Plans to enhance the RADR platform with agentic AI capabilities to improve drug development efficiency and precision.
Financial Position: Lantern closed 2024 with $24 million in cash, expected to fund operations for at least 12 months.
Future Funding Needs: Anticipates substantial additional funding will be needed in the near future.
Clinical Trial Milestones: Expecting multiple clinical readouts in 2025, particularly for LP-300 and LP-184.
Market Potential: Market potential for LP-300 is estimated at $4-5 billion annually, while LP-184 and STAR-001 could exceed $14 billion combined.
Burn Rate: Lantern's burn rate is significantly lower than industry peers, allowing for efficient advancement of clinical programs.
Cash Position: $24 million in cash, cash equivalents, and marketable securities as of December 31, 2024.
Net Loss: Net loss of approximately $20.8 million for the full year 2024.
Shares Outstanding: 10,784,725 shares of common stock outstanding.
Fully Diluted Shares: Approximately 12.1 million shares as of December 31, 2024.
Burn Rate: The burn rate is a fraction of that of other companies, with an average of about $2 million to $2.5 million per program from scratch to get it into a trial.
The earnings call indicates a positive sentiment due to the commercialization of the RADR AI platform with high predictive success, optimistic financial guidance, and strategic advancements like the withZeta AI system. Despite challenges in market conditions and regulatory hurdles, the company shows resilience with strategic execution and competitive positioning. The Q&A session provided clarity and positive updates, particularly on trials and AI platform rollout. The decrease in R&D expenses and slight improvement in net loss also contribute to a positive outlook, warranting a 'Positive' rating for the stock price movement.
The earnings call presents a mixed picture. The company beat EPS expectations, which is positive, but lacks clarity on shareholder returns and specific strategic details. The AI platform expansion and clinical trial progress are promising, yet the market faces risks from competition and regulatory issues. The Q&A session revealed some uncertainty about AI integration timelines and FDA processes. Without a clear market cap and given the absence of strong catalysts or new partnerships, the stock is likely to remain neutral in the short term.
The earnings call presents a mix of positive and negative elements. Financial performance shows a decrease in net loss and R&D expenses, but the need for additional funding is a concern. Product development and market potential are promising, but competition and regulatory risks persist. The Q&A section revealed some uncertainties, particularly around AI platform commercialization and funding. Positive aspects like geographic expansion and AI advancements are balanced by risks and funding needs, leading to a neutral sentiment. Without market cap information, the impact on stock price remains uncertain, suggesting a neutral prediction.
The earnings call reveals several negative aspects: increased losses, higher expenses, and unclear management responses regarding key programs and partnerships. Despite some positive developments in clinical trials, the financial health and guidance remain concerning. The expansion into Asia is promising, but supply chain risks and regulatory hurdles pose challenges. The lack of clarity in management's responses during the Q&A further adds to uncertainty, leading to a negative sentiment.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
